Nantahala Capital Management, LLC has disclosed a significant investment in Grace Therapeutics, Inc., revealing that it holds 7.45% of the company's common stock. This move is notable as it positions Nantahala as a key player in the pharmaceutical preparations sector, potentially influencing the company's future direction.

Grace Therapeutics, headquartered in Princeton, New Jersey, focuses on developing innovative therapies in the pharmaceutical industry. The company has undergone a name change from Acasti Pharma Inc. in 2008, reflecting its evolving business strategy. As of the latest filing, Grace Therapeutics continues to operate under the SIC classification of Pharmaceutical Preparations.

The recent filing, dated November 13, 2026, indicates that Nantahala Capital Management beneficially owns 1,654,393 shares of Grace Therapeutics. This stake includes shares that may be acquired through convertible securities, demonstrating Nantahala's commitment to its investment. The filing states, "As of September 30, 2026, Nantahala may be deemed to be the beneficial owner of 1,654,393 Shares held by funds and separately managed accounts under its control." This is a clear indication of Nantahala's strategic position in the company.

The filing also highlights the involvement of key individuals at Nantahala, including Wilmot B. Harkey and Daniel Mack, who are identified as control persons regarding the shares held by the firm. Each of these individuals also holds a 7.45% stake in Grace Therapeutics, reinforcing their influence within the company.

This development may impact various stakeholders, including current shareholders of Grace Therapeutics and other companies within the pharmaceutical preparations sector. The increased stake by Nantahala could lead to shifts in corporate governance discussions or strategic initiatives at Grace Therapeutics, prompting competitors to reevaluate their strategies in response.

Looking ahead, it remains unclear what specific actions Nantahala may pursue with its stake in Grace Therapeutics. The filing does not provide details on future plans or initiatives stemming from this investment. Investors and industry watchers will be keen to see how this situation unfolds in the coming months.